A follow-up analysis shows that the benefits of hormone therapy for the treatment of menopause symptoms outweigh the risks ...
More than two decades ago, the shocking results of a major women’s health study challenged the safety of menopause hormones, and overnight, millions of women and their doctors abandoned the ...
The findings, from two trials involving tens of thousands of women, could influence guidelines around the use of hormonal treatment for menopausal symptoms.
Researchers examined 453 menopausal women aged 40–65 with moderate or severe hot flushes who were unsuitable for hormone replacement therapy, after giving them 45mg of fezolinetant or placebo ...
Researchers found un-immediate relatives – ie grandparents, aunts, uncles, nieces and nephews – were 1.5 times more likely to get colon cancer if their relative had started the menopause early ...
Women who start the menopause before the age of 40 are more likely to die young, new research suggests. Most women experience menopause between the ages of 45 and 55. But around one in 100 go ...
Moderate to severe hot flashes may triple the risk of metabolic dysfunction steatotic liver disease, a study suggests.
Research, by her menopause clinic Newson Health, found almost a third of women had between two and five medical appointments before their symptoms were diagnosed as linked to the perimenopause and ...
(WJAR) — When it comes to preventing skin cancer and wrinkles, sunscreen is the gold standard -- as long as it works. A new study from the Environmental Working Group, which looked at more than ...
An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer, according to results released Thursday from two studies involving tens of ...
Fezolinetant reduces the frequency and severity of hot flushes during menopause for 24 weeks, without serious side effects, according to research presented at the 26th European Congress of ...